US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
News
Cytox gets £800,00 from Innovate UK
Cytox has been awarded funding from Innovate UK for the clinical evaluation of its pioneering approach to Alzheimer’s disease risk assessment.
RCEM calls for public action on A&E crisis
The Royal College of Emergency Medicine is urging patients to lobby MPs for action to address the “serious challenges” facing Emergency Departments across the UK.
Finalists announced!
Following a meeting of the executive steering group, PharmaTimes Media is delighted to reveal the 2018 International Clinical Researcher of the Year finalists…
UCB’s Vimpat gets NHS green light in Wales
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
NICE u-turn on treatment for giant cell arteritis
Roche/Chugai’s RoActemra has now won the backing of the National Institute of Health and Care Excellence for the treatment of eligible patients with giant cell arteritis (GCA).
UK launch for Europe’s first Herceptin biosimilar
MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
US green lights novel HIV treatment
US regulators have approved a new option for treating HIV, marking the first therapy with a new mode of action in a decade.
EMA recommends suspension, recall of Zinbryta
The European Medicines Agency is now recommending the immediate suspension and recall of Biogen’s multiple sclerosis therapy Zinbryta, just days after announcing a safety review.
BI, Lilly expand Jardiance programme in heart failure
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
BMS’ Opdivo cleared for monthly use
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks.
Gedeon’s re-filed Neulasta biosimilar under EU review
European regulators have accepted a resubmission of Gedeon Richter’s biosimilar to Amgen’s Neulasta.
PHE campaign calls on the UK to diet
Public health officials in the UK are calling on people in the UK to reduce their calorie intake in a bid to cut back on levels of obesity and related conditions, which are putting a huge strain on healthcare resources.
Novartis’ Xolair backed in global urticaria guidelines
Novartis’ Xolair has been recommended in global guidelines for treating chronic spontaneous urticaria in patients unresponsive to antihistamines.
Santhera’s Raxone fails in MS trial
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.
